Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.
about
Regulation of PP2A by Sphingolipid Metabolism and SignalingPreclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-MitoxyOverview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.Fingolimod for relapsing multiple sclerosis: an update.Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis.FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value.A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjectsFingolimod: a novel immunosuppressant for multiple sclerosis.FTY720 (fingolimod) for relapsing multiple sclerosis.Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.Clinical pharmacokinetics of fingolimod.Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators.Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study.FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.Change in vital signs after fingolimod initiation in patients with multiple sclerosis: the possible need for 24 h monitoring.Population pharmacokinetics of fingolimod phosphate in healthy participants.FTY720 pharmacokinetics in mild to moderate hepatic impairment.Fingolimod (Gilenya® ) in multiple sclerosis: bradycardia, atrioventricular blocks, and mild effect on the QTc interval. Something to do with the L-type calcium channel?A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function.Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy Subjects.A review of bioanalytical quantitative methods for selected sphingosine 1-phosphate receptor modulators.MS565: A SPECT Tracer for Evaluating the Brain Penetration of BAF312 (Siponimod).Mitigation of Initial Cardiodynamic Effects of the S1P1 Receptor Modulator Ponesimod Using a Novel Up-Titration Regimen.Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm.
P2860
Q27026038-73F00FB7-2DB3-4028-87D4-F70D8750A368Q28553993-07B0ED19-1DC7-4F18-A477-EC8E22B86647Q30458371-79F6CDBE-B393-4FFE-8D9C-4C18D76DE7CEQ30838717-A4221587-7CA6-4740-80DA-448151213412Q33829582-A593D36F-46DF-4C1E-AF23-F58FAA91B8FAQ33881977-54756AD7-4790-4589-A549-0A9BDA5881BFQ34150336-C662B2E1-5B54-4861-919C-3FDF1A8A2389Q34518822-C48D5E42-3E5E-425D-85B5-770C8446A763Q34618474-7EAA1646-D115-47B9-9004-84F63564BAD4Q34729032-0F19D1EE-1304-4B10-B1C3-33A4AE86ED6BQ35876398-B3E806E0-94A0-408B-9423-9560B569FB1DQ35953902-C97678F1-42A7-4D45-8D52-8A955D6345F3Q36803411-CB4D83D5-AE81-4A36-AC96-99704839C9C9Q36929186-7FB78D13-AEA6-4BC5-90F2-C46622B284F9Q37154788-23FEEC89-34FA-41C9-B22D-E295A36D778FQ37890469-E6F2A006-B89C-4712-8994-37E0A6C3D1FBQ37905767-30FCEEB3-E354-40C8-BE88-A88DA7C28D4FQ37930972-3640BD86-5C49-4D4A-B479-A81A87074241Q37965580-C4FE13C4-E8E5-4E26-B5CA-18004D8BF9A6Q38850104-8ED0306E-4421-48AF-BF65-0BDB5E0E72EAQ39771285-6CDE5E5D-70C2-46CB-BBEB-5F3103036BC6Q41052913-6E2ABE00-453C-4225-87AA-BBD6D257643BQ42016913-852FF24E-484A-44FF-BFF7-314D717914C7Q42626937-6E391966-1081-44EA-A128-AF0DD8A3AB40Q43246572-D6BB66D3-C73D-4544-ADB3-5005550D3B82Q45171971-AA089741-E04B-425E-8D61-4DAE9C3C8E8CQ46391230-B6D0D3F2-38A2-4F1A-8705-E719AC5281C3Q46480858-AC6B6E5F-1113-4AC4-9E37-3CD69E2F55A4Q46792453-4C59A075-7905-4F66-8BC3-5B65955730C8Q46908020-C616E53F-1824-4C78-A6F8-C9EE8D71080AQ47430919-FAF7C3B2-6A53-48FC-9DF8-C33CF740AC2FQ47679381-E44F1DCE-BF9B-4113-BE21-424D30C916D9Q48202325-8D2D3DB5-0A72-4047-A0EA-D11C6A2F4949Q51552299-5AA58395-620B-41FB-82AE-EB79B13E2AC7Q52952840-D8C534BA-12BA-44B1-B593-116B769B9EF0
P2860
Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Single-dose FTY720 pharmacokin ...... responses in healthy subjects.
@en
Single-dose FTY720 pharmacokin ...... responses in healthy subjects.
@nl
type
label
Single-dose FTY720 pharmacokin ...... responses in healthy subjects.
@en
Single-dose FTY720 pharmacokin ...... responses in healthy subjects.
@nl
prefLabel
Single-dose FTY720 pharmacokin ...... responses in healthy subjects.
@en
Single-dose FTY720 pharmacokin ...... responses in healthy subjects.
@nl
P2093
P2860
P1476
Single-dose FTY720 pharmacokin ...... responses in healthy subjects.
@en
P2093
Denise Barilla
Gerolf Kraus
John M Kovarik
Robert Schmouder
Yibin Wang
P2860
P304
P356
10.1111/J.1365-2125.2003.02065.X
P407
P577
2004-05-01T00:00:00Z